Clinical trials: Doxorubicin
Chemotherapy-induced Neutropenia
Dose-finding Study of Empegfilgrastim for Neutropenia Prophylaxis in Patients With Breast Cancer
The purpose of the study is to compare safety and efficacy of a single dose of empegfilgrastimt a dose of 3 or 6 mg versus daily administration of filgrastim at a dose of 5 μg/kg/day.
- Trial name
- NCT01569087
- Testing
- empegfilrastim, filgrastim
- Where
- 5 sites in Russia
- Volunteers
- 60 people
- Sponsor
- Biocad
Chemotherapy-induced Neutropenia
Study of the Efficacy and Safety of Empegfilgrastim for Neutropenia Prophylaxis in Breast Cancer Patients
The purpose of the study is to compare safety and efficacy of a single dose of empegfilgrastim and daily dosing of filgrastim for prevention of neutropenia in patients receiving AT (docetaxel 75 mg/m2 + doxorubicin 50 mg/m2).
- Trial name
- NCT02104830
- Testing
- Empegfilrastim 6 mg, Filgrastim, Empegfilrastim 7.5 mg
- Where
- 13 sites in Russia
- Volunteers
- 135 people
- Sponsor
- Biocad
Ovarian Neoplasms
Phase II Clinical Study of Pegylated Liposomal Doxorubicin Hydrochloride Injection as 2nd-line or Later Therapy in Patients With Mullerian Carcinoma (Epithelial Ovarian Carcinoma, Primary Carcinoma of Fallopian Tube, Peritoneal Carcinoma) Having Prior Platinum-Based Chemotherapy
The purpose of this study is to assess the effectiveness and safety of pegylated liposomal doxorubicin hydrochloride injection in Japanese patients with Mullerian carcinoma.
- Trial name
- NCT00216645
- Testing
- doxorubicin hydrochloride
- Volunteers
- 74 people
- Sponsor
- Janssen Pharmaceutical K.K.
Relapsed Follicular Lymphoma
Phase 2 Study of VELCADE (Bortezomib) in Patients With Relapsed Follicular Lymphoma
This is a phase 2, two-arm, non-randomized, open-label, multicenter study evaluating the safety and efficacy of 2 VELCADE-containing regimens.
- Trial name
- NCT00715208
- Testing
- rituximab, cyclophosphamide, doxorubicin
- Where
- 43 sites in United States, Puerto Rico
- Volunteers
- 55 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Carcinoma, Hepatocellular
Efficacy and Safety Doxorubicin Transdrug Study in Patients Suffering From Advanced Hepatocellular Carcinoma
The purpose of this phase III study is to determine whether Doxorubicin Transdrug (DT) is effective in the treatment of patients suffering from advanced Hepatocellular Carcinoma (HCC) after failure or intolerance to Sorafenib.
- Trial name
- ReLive (NCT01655693)
- Testing
- Doxorubicin 20 mg/m2, Doxorubicin 30 mg/m2, Best Standard of Care
- Where
- 70 sites in United States, Austria and 9 more
- Volunteers
- 397 people
- Sponsor
- Valerio Therapeutics
Diffuse Large B-Cell Lymphoma
A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections).
- Trial name
- EPCORE DLBCL-2 (NCT05578976)
- Testing
- Epcoritamab, Cyclophosphamide, Rituximab
- Where
- 331 sites in United States, Australia and 29 more
- Volunteers
- 900 people
- Sponsor
- Genmab
HER2 Negative Metastatic Breast Cancer
Ph 1 ADI-PEG 20 Plus Doxorubicin; Patients With HER2 Negative Metastatic Breast Cancer
Certain cancers require the amino acid arginine. Arginine deiminase (ADI) is an enzyme from microbes that degrade arginine. ADI has been formulated with polyethylene glycol, and has been used to treat patients that have cancers…
- Trial name
- NCT01948843
- Testing
- ADI-PEG 20
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Polaris Group
Advanced Malignancies
A Clinical Trial to Evaluate AZD7648 Alone and in Combination With Other Anti-cancer Agents in Patients With Advanced Cancers.
This is a modular Phase I/IIa, open-label, multi-centre, study of AZD7648 administered orally, either as a monotherapy, or in combination with either cytotoxic chemotherapies or novel anti-cancer agents in participants with…
- Trial name
- NCT03907969
- Testing
- AZD7648, PLD
- Where
- 5 sites in United States, United Kingdom
- Volunteers
- 30 people
- Sponsor
- AstraZeneca
Hepatocellular Carcinoma
Study of ThermoDox With Standardized Radiofrequency Ablation (RFA) for Treatment of Hepatocellular Carcinoma (HCC)
The purpose of this study is to determine whether ThermoDox, a thermally sensitive liposomal doxorubicin, is effective in the treatment of non-resectable hepatocellular carcinoma when used in conjunction with standardized…
- Trial name
- OPTIMA (NCT02112656)
- Testing
- ThermoDox, Dummy infusion
- Where
- 61 sites in United States, Canada and 12 more
- Volunteers
- 554 people
- Sponsor
- Imunon
Advanced Cancer
Phase 1 Study of ZIO-201-T in Combination With Doxorubicin in Solid Tumors
The study of safety of ZIO-201-T in combination with doxorubicin in the treatment of advanced cancer.
- Trial name
- NCT00608803
- Testing
- ZIO-201-T and doxorubicin
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Alaunos Therapeutics
Breast Cancer
A Study of Docetaxel Monotherapy or DOXIL and Docetaxel in Patients With Advanced Breast Cancer
The purpose of the study is to evaluate whether the time to progression for the DOXIL and docetaxel combination therapy group was superior to that of the group treated with docetaxel monotherapy in participants with advanced…
- Trial name
- NCT00091442
- Testing
- Docetaxel, DOXIL
- Where
- 147 sites in United States, Bulgaria and 16 more
- Volunteers
- 751 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.